The determination of fetal RHD genotyping in maternal blood allows:
- Establish if a negative RhD pregnant woman requires the immunoprophylaxis vaccine administration.
- The management of a risky pregnancy, in RhD negative pregnants with anti-D, to determine if the fetus is at risk of Haemolytic Disease of the fetus and Newborn (EHRN).
- Avoid the unnecessary administration of anti-D immunoglobulin, in case of negative fetal RhD genotype, thus avoiding its associated risk.
- Increase the availability of anti-D immunoglobulin for use after potential sensitization events (PSE) in pregnancies where the result of Non-invasive Prenatal Diagnosis (NIPD) for the fetal RhD genotype is positive.
- Avoid unnecessary painful injections for women in whom Non-Invasive Prenatal Diagnosis for the fetal RhD genotype is negative.
- Reduce the number of prenatal appointments for prophylactic anti-D treatment and the amount of anti-D immunoglobulin used.
- Reduce the anxiety associated with potential sensitization events for RhD negative women when the outcome of NIPD for the fetal RhD genotype is negative.
- Provide information to allow RhD negative women to make an informed decision about whether or not they should receive anti-D immunoglobulin treatment based on the outcome of the fetal genotype.
Non-invasive test performed from maternal plasma
Collection in EDTA tubes
Samples collected after 11 weeks of gestation
Based on Real Time PCR technique (RT-PCR)
Amplification of three exons of the RHD gene (exons 5, 7 and 10)
RT-PCR Instruments previously validated:
- Dx RealTimeSystem (BioRad)
- LightCycler480 (Roche)
- LightCycler2 (Roche)